Carlsbad-based biopharmaceuticals developer Isis Pharmaceuticals said this morning that it has earned $2M from GlaxoSmithKline, related to advancement of a compound in Phase 2/3 studies. The company said the milestone payment from GSK was related to its ISIS-TTRRx studies aimed at patients with familial amyloid polyneuropathy (FAP). Isis said the $2M is part of $50M in potential milestone payments that Isis is eligible to earn from GlaxoSmithKline.
Top NewsMonday, December 2, 2013
Isis Pharmaceuticals Earns $2M From GlaxoSmithKline